PharmAsia News India Pharma Roundup: Jubilant Organosys, Drug Price Cuts, Pharma Advisory Forum, Ranbaxy
This article was originally published in PharmAsia News
NEW DELHI - India's Jubilant Organosys' $225 million all-cash deal for Canada's Draxis Health provides the company a path to consolidate contract manufacturing in North America with a contract in hand to launch a generic version of Johnson & Johnson's imaging agent Cardiolite in 2008 and time to mull whether to retain the company's currently high margin but increasingly competitive radiopharmaceutical business, Kotak Institutional Equities said
You may also be interested in...
NEW DELHI - Indian Chemicals Minister Ram Vilas Paswan is making an all out effort to get the country's draft pharmaceutical policy cleared by the Group of Ministers in its next meeting
NEW DELHI - India's growing success in the pharmaceutical custom research and manufacturing services sector is demonstrated by Jubilant Organosys netting CRAMS contracts totaling $92 million for 2008, with most contracts coming from Japan, China, the U.S. and Europe, the Uttar Pradesh-based manufacturer said Feb. 2
NEW DELHI - Indian Finance Minister Palaniappan Chidambaram said a 150 percent research and development tax rebate for drug firms would be extended to contract outsourcing work at a 125 percent rebate as he slashed duties on a variety of bulk drugs and pharmaceuticals in the country's proposed $192 billion budget for the fiscal year starting April 1